International journal of fertility and menopausal studies · 1995
Use of gonadotropin releasing hormone agonist following follicular aspiration in donor oocyte program--impact on subsequent menstruation.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ng S T, Wu T C
Аннотация
OBJECTIVE: The present study evaluated the impact of continuous administration of gonadotropin-releasing hormone agonist (GnRH-a) following oocyte retrieval of oocyte donors in a donor oocyte program.
PATIENTS AND METHODS: Six patients from a donor oocyte program who underwent controlled ovarian hyperstimulation with midluteal GnRH-a and human menotropin had more than 20 mature ovarian follicles and serum estradiol levels > or = 3,000 pg/mL on the day of human chorionic gonadotropin administration. These patients resumed the use of GnRH-a immediately following follicular aspiration. Three patients continued daily injection until the onset of next menses, while three took it irregularly, due to poor compliance.
RESULTS: Only one of the three patients who administered GnRH-a daily developed mild symptoms of ovarian hyperstimulation, and all resumed menstruation within 13 days following aspiration. All three patients who failed to comply, and used GnRH-a sporadically, developed symptoms of ovarian hyperstimulation and experienced delayed menstrual periods. One of these three patients required hospitalization.
CONCLUSION: Our data suggest that continuous postaspiration GnRH-a use may be beneficial for oocyte donors whose ovaries are hyperstimulated. Sporadic administration of GnRH-a is not effective and may delay the resumption of spontaneous menstruation.
PATIENTS AND METHODS: Six patients from a donor oocyte program who underwent controlled ovarian hyperstimulation with midluteal GnRH-a and human menotropin had more than 20 mature ovarian follicles and serum estradiol levels > or = 3,000 pg/mL on the day of human chorionic gonadotropin administration. These patients resumed the use of GnRH-a immediately following follicular aspiration. Three patients continued daily injection until the onset of next menses, while three took it irregularly, due to poor compliance.
RESULTS: Only one of the three patients who administered GnRH-a daily developed mild symptoms of ovarian hyperstimulation, and all resumed menstruation within 13 days following aspiration. All three patients who failed to comply, and used GnRH-a sporadically, developed symptoms of ovarian hyperstimulation and experienced delayed menstrual periods. One of these three patients required hospitalization.
CONCLUSION: Our data suggest that continuous postaspiration GnRH-a use may be beneficial for oocyte donors whose ovaries are hyperstimulated. Sporadic administration of GnRH-a is not effective and may delay the resumption of spontaneous menstruation.